Weekly Recap | FOSUN PHARMA -5.88%, most brokers rate it buyWeekly Review·Sep 12 at 05:30 AM02196+0.99%
Weekly Recap | FOSUN PHARMA -1.79%, consensus target above spotWeekly Review·Aug 29 at 04:29 AM02196+0.99%
FOSUN PHARMA: Subsidiary HLX97 approved for clinical trials for the treatment of advanced/metastatic solid tumorsWallstreetcn·Mar 5 at 10:24 AM02196+0.99%600196+1.15%
FOSUN PHARMA rose in both the mainland and Hong Kong markets, with A-shares and Hong Kong stocks increasing by nearly 4% and nearly 6%, respectively. Previously, the company announced that its subsidiary signed a licensing agreement with Pfizer for GLP-1R agonists, potentially worth up to $500 millionWallstreetcn·Dec 10, 2025 at 01:48 AM600196+1.15%02196+0.99%
The "Dual Catalog" of medical insurance and commercial insurance has been released, with products from multiple innovative pharmaceutical companies making the listWallstreetcn·Dec 8, 2025 at 10:12 PM600276+1.57%600196+1.15%
